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SustainedAbstract 5-Fluorouracil is used in the treatment of colorectal cancer along with oxaliplatin as ﬁrst
line treatment, but it is having lack of site speciﬁcity and poor therapeutic effect. Also toxic effects
to healthy cells and unavailability of major proportion of drug at the colon region remain as limita-
tions. Toxic effects prevention and drug localization at colon area was achieved by preparing enter-
ic-coated chitosan polymeric nanoparticles as it can be delivered directly to large bowel. Enteric
coating helps in preventing the drug degradation at gastric pH. So the main objective was to prepare
chitosan polymeric nanoparticles by solvent evaporation emulsiﬁcation method by using different
ratios of polymer (1:1, 1:2, 1:3, 1:4). Optimized polymer ratio was characterized by differential scan-
ning calorimetry (DSC), X-ray diffraction (XRD), entrapment efﬁciency and particle size and fur-
ther subjected to enteric coating. In vitro drug release studies were done using dialysis bag technique
using simulated ﬂuids at various pH (1.2, 4.5, 7.5, 7.0) to mimic the GIT tract. 5-FU nanoparticles
with drug: polymer ratio of 1:2 and 1:3 has shown better particle size (149 ± 1.28 nm and
138 ± 1.01 nm respectively), entrapment efﬁciency (48.12 ± 0.08% and 69.18 ± 1.89 respectively).
5-FU E1 has shown better drug release after 4 h and has shown 82% drug release till 24 h in a sus-
tained manner comparable to the non-enteric coated tablets, which released more than 50% of the
drug before entering the colon region. So we can conclude that nanoparticles prepared by this
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approach for effective delivery of the active pharmaceutical ingredient to the colorectal tumors.
ª 2014 TheAuthors. Production and hosting by Elsevier B.V. on behalf of King SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Among the various types of cancers, colorectal cancer is a sig-
niﬁcant source of morbidity and mortality in the United States
and other Western countries. The cancer is one of the most
dreaded and threatening diseases in the world, causing more
than 6 million deaths a year (Ramanathan et al., 2003).
Colorectal cancer is the second leading cause of death followed
by lung cancer (Dhawale et al., 2010).
Various cytotoxic drugs are used for the treatment of col-
orectal cancer like 5-Fluorouracil, Oxaliplatin, and Cisplatin.
The ﬁrst line treatment generally includes the combination of
5-ﬂuorouracil and oxaliplatin by intravenous administration.
The rationale behind using cytotoxic drug over others is their
toxicity to the cells that are rapidly dividing which can be
attributed to the fact that cancer cells undergo rapid growth
proliferation. Most of these drugs are administered by intra-
venous route to attain maximum bioavailability, still treatment
failure is observed for most of the cytotoxic drugs. The main
problem for the treatment failure is the drug inability to act
particularly at the target site, which leads to lack of site speci-
ﬁcity leading to the side effects to both healthy cells and tumor
cells by the drug. Some of the other limitations associated with
the anti cancer drugs are their hydrophobic nature, improper
biodistribution and their susceptibility to develop drug resis-
tance (Wong et al., 2007; Duran et al., 2008).
Therapeutic strategies currently used in the treatment of
colorectal cancer are chemotherapy, surgery, radiation and
biological therapies (immuno therapy and hormonal therapy).
The beneﬁts of traditional chemotherapy are limited by the
toxicity associated with anticancer drugs in healthy tissues.
The common features of cancer and healthy cells make it dif-
ﬁcult to achieve pharmacoselectivity of drugs at the target site
(Cirstoiu-Hapcaa et al., 2009).
Lack of site speciﬁcity is one of the major reasons for the
drug in reaching the target site in therapeutic concentrations
in colorectal cancer (Michor et al., 2005; Krishnaiah and
Satyanarayan, 2001). Generally in order to compensate the
lack of site speciﬁcity, increase in the dose size is preferred
which leads to various toxicities. Researchers have proved tar-
geting the drug to the tumor tissues. Also localization of the
drug at the colon area helps in getting drug released at colon
region leading to the major amount of the drug entering the
colon. Coating the drugs with various polymeric substances
like cellulose derivatives (Levine et al., 1987) and acrylic poly-
mers (Rasmussen et al., 1982) can deliver them directly to large
bowel. The main rationale behind using these types of poly-
mers is their ability to prevent drug degradation in the gastric
environment in the stomach and their ability to release the
drug after entering the distal ileum (Levine et al., 1987;
Rasmussen et al., 1982).
5-Fluorouracil (5-FU or 5-ﬂuoro-2,4-pyrimidinedione) has
broad spectrum of activity with a broad spectrum of activity
against solid tumors (of the gastrointestinal tract, pancreas,ovary, liver, brain, breast, etc.), alone or in combination with
chemotherapy regimes. The mechanism behind the cytotoxicity
and cell death activity of 5-FU is its interference with nucle-
oside metabolism in RNA and DNA (Arias, 2008).
To maintain therapeutic serum concentration, constantly
dose administration of 5-Fluorouracil has to be given leading
to severe toxic effects after certain limit (Zhang et al., 2008b;
Arias et al., 2008). The overall response rate for advanced col-
orectal cancer of 5-FU alone is still only  10%, and the com-
bination of 5-FU with other antitumor drugs has merely
improved the response rates to just  45%. 5-FU injection is
generally used with the speciﬁcation of 0.25 g/10 ml (Grem,
2000; Malet-Martino and Martino, 2002).
So the main objective is to develop 5-ﬂuorouracil chitosan
nanoparticles with different polymer ratios using solvent emul-
siﬁcation evaporation method. Eudragit L-100 polymer was
used which can provide enteric coating thereby protecting
the drug at acidic environment in the stomach and releasing
the drug at basic pH starting from the intestine to colon. The
other novelty associated with this study is the administration
of the nanoparticles orally to improve the patient compliance
and also making available the dosage form directly to large
bowel via the GIT tract so as to localize the maximum amount
of drug in the colon area and also attaining the sustained
release.2. Materials and methods
2.1. Materials
5-Fluoro uracil, used as active pharmaceutical ingredient was
obtained from Sigma Aldrich, Mumbai. Chitosan (puriﬁed),
used as polymer was obtained from M/s Panacea Biotech,
Chandigarh, India. Eudragit S100, used for enteric coating
was obtained from Degussa, Germany. Dialysis bag and tri-
ethyl citrate were purchased from Himedia. Polyvinyl alcohol
was obtained from BDH Laboratories. All other chemicals
were of analytical grade. Doubly distilled water was used
throughout the study.
2.2. Preparation of chitosan polymeric nanoparticles
The method used for the preparation of chitosan nanoparticles
containing 5-FU is solvent emulsiﬁcation evaporation tech-
nique. Different ratios of drug: polymer (1:1, 1:2,1:3, 1:4)
was selected in order to optimize the best one and also to
observe the effect of polymer on the formulation.
Acetic acid was used as organic solvent and PVA as surfac-
tant in a ﬁxed concentration of (0.5% w/v). Drug was dis-
solved in 40 ml water with varying polymer ratios (1:1, 1:2,
1:3, 1:4). Then it was followed by addition of aqueous surfac-
tant polyvinyl alcohol using high speed emulsiﬁer and was stir-
red continuously for 3 h. Then the emulsion was subjected to
310 S. Tummala et al.centrifugation (SIGMA, Germany) for 30 min at 12,000 rpm.
Supernatant was removed and washed repeatedly three times
and subjected to lyophilization using 1% mannitol as cryopro-
tectant (Christ Alpha 2-4 LD, Freeze Drying Solutions, UK).
2.3. Preparation of pellets and Enteric coating of nanoparticles
(Jain et al., 2010)
The nanoparticles were made into pellets by extruder-
spheronization technique(UFEE 60; Umang Pharmatech,
Ahmedabad, India). Wet mass was formed by mixing the
nanoparticles with deionized water and avicel which was
extruded with an extruder having a sieve opening of 1 mm,
screen thickness of 2.5 mm and extrude cut-off length of
approximately 2–4 mm. then the extrudes were spheronized
in a spheronizer at 2200 rpm for 10 min. Pellets formed were
dried at 35–40 C and subjected to enteric coating.
Enteric coating was done by conventional coating pan used
in the laboratory. The conditions followed for the coating of
the pellets were pan rotating speed at 20 rpm, atomizing air
pressure of 2 bar; inlet air temperature of 60–70 C; outlet
air temperature of 35–40 C. The coating solution was pre-
pared by mixing Eudragit S100 with ammonia and triethyl
citrate (which was an active ingredient generally used in coat-
ing process) and stirred properly was applied through 1.1 mm
spray nozzle (Huyghebaert et al., 2005). Pellets were kept coat-
ed in the pan till they achieve complete weight gain. All the pel-
lets were stored in a vacuum dessicator at room temperature
until used.
2.4. Characterization of nanoparticles
2.4.1. Differential scanning calorimetry (DSC)
DSC analysis was performed using DSC Q200, TA instru-
ments, Mumbai, India. The samples were heated in a sealed
aluminum pans at a rate of 10 C per/min in a 30–300 C tem-
perature under nitrogen ﬂow of 40 mL/min. DSC analysis was
performed for PLGA, Eudragit L100, Gliclazide, physical mix-
ture of polymer and drug and ﬁnally for GL-PLGA, GL-EU
polymeric nanoparticles.
2.4.2. X-ray diffraction studies (XRD) (Badry et al., 2009)
Molecular arrangements of drug gliclazide in nanoparticulate
formulations were performed on an X-ray diffractometer
(PANalytical X’pert PRO; Lelyweg, Almelo, The Netherlands)
using Cu Ka radiation. The data were collected over an angu-
lar range from 3 to 50 2h in continuous mode using a step
size of 0.02 2h and step time of 5 s.
2.4.3. Particle size and zeta potential (Naik et al., 2013)
The average particle size and zeta potential of the PLGA-Gli-
clazide and EU-gliclazide nanoparticles were determined by
Particle Size Analyzer (Zetasizer Ver System; Malvern Instru-
ments Ltd., Malvern, UK). To analyze particle size, nanosus-
pension was diluted with ﬁltered (0.22 lm) ultra pure water.
2.4.4. Drug content and entrapment efﬁciency (Avinash et al.,
2007)
Nanoparticles (20 mg) after freeze-drying were added to their
speciﬁc solvent (10 ml) to facilitate the coat of the nanoparti-cles to get dissolved. The resultant suspension was subjected
to evaporation for further removal of the solvent prior to ﬁl-
tration. Then the residue was washed and diluted appropriate-
ly with phosphate buffer of pH 6.8 to determine drug content
and entrapment efﬁciency. Samples were measured at an
absorbance of 269 nm in Double beam U.V Spectrophotome-
ter. Drug content loading and entrapment efﬁciency of gli-
clazide in nanoparticles were determined by the following
equations:
Drug loading contentð%w=wÞ¼ Weight of drug in nanoparticle
Weight of nanoparticle recovered
100
Entrapment efficiencyð%Þ¼Weight of the drug in nanoparticle
Weight of the drug fed initially
1002.4.5. Statistical analysis
Statistical analysis was performed for different formulae by
applying one-way analysis of variance ANOVA test. Further
difference between two formulations was determined by paired
t-test using statistical software package (Minitab express and
Minitab 17). The differences were considered statistical sig-
niﬁcant based on the p-value whether it is equal or less than
0.05.
2.4.6. Scanning electron microscopy (SEM) (Mohideen et al.,
2013)
Scanning electron microscopy (SEM) was used to verify uni-
formity of particle shape and size. Freeze-dried nanoparticles
were resuspended in distilled water and were later dropped
onto a silicon grid and dried under room temperature. The
nanoparticle suspension was vacuum coated with gold for
3 min. The surface morphology of the samples was observed
under a scanning electron microscope (JEOL–JAPAN) operat-
ed at 15-keV pulse at different resolutions.
2.4.7. In vitro drug release study (Jain et al., 2010)
In vitro drug release study was carried out using USP Dissolu-
tion apparatus (Type II). Enteric-coated chitosan nanoparti-
cles were tested in various simulated ﬂuids at different pH to
evaluate the release of nanoparticles at particular pH and also
to determine the drug release and localization. Dialysis bag
method was preferred and nanoparticles were placed in a bea-
ker containing 100 ml of simulated ﬂuids at 37 ± 0.5 C with a
dialysis bag with molecular weight cut-off of 3500. The
simulated ﬂuids were maintained at proper sink conditions
under continuous magnetic stirring. Various simulated ﬂuids
with pH 1.2 (indicative of gastric pH), 4.5 (indicative of gastric
and intestinal ﬂuid pH), 7.5 (indicative of intestinal ﬂuid pH), 7
(colon pH). These ﬂuids were changed according to the time
intervals assuming that the drug keep on passing the GIT.
So the ﬂuids pH was changed accordingly to the area, which
it was going to reach to calculate drug release effectively. First
one hour was considered for gastric pH, 2–3 h was considered
as mixture of gastric ﬂuid and intestinal ﬂuid with pH 4.5, 4–
5 h was considered as intestinal ﬂuid with pH 7.5 and 6–8 h
were considered as colonic ﬂuid with pH 7.0. Samples were
withdrawn and the same amount was replaced using the same
simulated ﬂuid. The amount of the drug was quantiﬁed using
double beam U.V spectrophotometer at 269 nm.
Figure 1 DSC thermograms of (A) 5-FU (B) chitosan (C)
chitosan polymeric nanoparticles (D) Eudragit S-100 and (E)
enteric coated chitosan polymeric nanoparticles.
Figure 2 XRD patterns of (A) 5-FU (B) chitosan (C) Eudragit
and (D) enteric coated polymeric nanoparticles.
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3.1. Differential scanning calorimetry (DSC)
Thermogram of 5-Fluorouracil, chitosan, chitosan polymeric
nanoparticles, Eudragit S-100 and Enteric coated polymeric
nanoparticles was illustrated in Fig. 1. The DSC curve of 5-
FU exhibits corresponding peak at peak temperature of
265.8 C corresponding to its melting point. Polymers chitosan
and Eudragit S-100 has shown peaks at a temperature of 82
and 172.5 C respectively. 5-Fluoro uracil chitosan polymeric
nanoparticles have shown a minor peak at 82 C and peak
position at 5-FU was found to be vanished, which can be
attributed to the fact that drug can be molecularly dispersed
into the polymer matrix. Enteric coated nanoparticles thermo-
gram has shown peaks at 75.89 C, 162.15 C and a minor
peak at the area where 5-FU present. These studies further
strengthen the evidence that there is compatibility between
the drug and the polymers and also the chance of entrapment
of drug inside the polymer in the polymeric nanoparticles. Also
the presence of polymer reduces the height and sharpness of
the peaks, which can be observed in case of polymeric
nanoparticles. The DSC studies support our rationale, as sta-
bility is the primary concern, which can effect the formulation
in many ways. To achieve stability, compatibility between the
drug and the polymer must be ensured which can be conﬁrmed
by the DSC and further by XRD studies.
3.2. XRD studies
An XRD peak mainly depends on the crystal size as they indi-
cate the crystalline nature at particular value at 2h range. In
this study, pure drug 5-ﬂuoro uracil had shown a sharp single
peak and the highest one at 2h equals 16.1 that indicates its
crystalline nature. Polymers chitosan and Eudragit S-100
diffractograms had shown peaks at 18 and 14 respectively
which can be seen in Fig. 2. The diffractograms of pure
polymer were found to be different from the drug loaded poly-meric nanoparticles, as we noticed a little decrease in the inten-
sity of the peak which can be attributed to the lower level of
detection of the encapsulated drug as it was dispersed in mole-
cular level and moreover the slight disappearance of the 5-
ﬂuoro uracil peak indicates the entrapment of drug inside
the polymers and also indicates the amorphous state of the
encapsulated drug. Also the enteric-coated polymeric nanopar-
ticles XRD peak was found to be of lower intensity and detec-
tion was found to be little difﬁcult as they were enteric coated
along with the chitosan polymeric nanoparticles.
3.3. Particle size and zeta potential analysis
The mean particle size of 5-FU nanoparticles was found to be
smaller than 192 nm. So the nanoparticles size range was
found to be satisfactory and was according to the speciﬁca-
tions. This was performed in replicate of three times (n= 3)
in order to ensure reproducibility to minimize the error. PDI
values were found to be lesser than 0.2, which indicates that
the system has a relatively narrow distribution. Zeta potential
was found to be in the limit and it further proves the stability
of the prepared polymeric nanoparticles, which justiﬁes the
rationale of preparing stable nanoparticles, as stable nanopar-
ticles can be easily dispersed which enhances its solubility. The
results evaluated were shown for different ratios of drug: poly-
mer in Table 1. The particle size intensity for drug: polymer
ratios of 1:3 and 1:2 were 138 ± 1.01 nm and 149 ± 1.28 nm
respectively which can be seen in Fig. 3. Both these ratios were
found to be satisfactory and can be optimized among the all by
evaluating the entrapment efﬁciency, which was conﬁrmed
later.
3.4. Drug loading and entrapment efﬁciency studies
The reason behind selecting polymeric nanoparticles over solid
lipid nanoparticles is their ability to get drug incorporated and
also exhibit more encapsulation efﬁciency. Entrapment efﬁ-
ciency is considered as an important parameter as improper
entrapment leads to the initial burst release of the drug, which
Table 1 Particle size, entrapment efﬁciencies and drug loading (%) of 5-FU polymeric nanoparticles.
Drug: polymer ratio Particle size (nm) Entrapment eﬃciency (%) Drug loading (%)
1:1 192 ± 0.15 26.89 ± 0.09 17.51 ± 0.018
1:2 149 ± 1.28 48.12 ± 0.08 12.10 ± 0.027
1:3 138 ± 1.01 69.18 ± 1.89 28.14 ± 0.19
1:4 187 ± 0.09 32.18 ± 0.47 15.91 ± 1.25
Figure 3 Average particle size of 5-FU (1:3) chitosan
nanoparticle.
Figure 4 SEM image of GL-PLGA nanoparticles and GL-EU
nanoparticles.
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tic dose has to be available for the formulation to achieve
required therapeutic effect. Entrapment efﬁciency of all the
polymer nanoparticles made of different polymer ratios was
shown in Table 1.
Based on the evaluation parameters of entrapment efﬁcien-
cy and drug content, 5-FU polymeric nanoparticles of ratio 1:3
(138 ± 1.01 nm) and 1:2 (149 ± 1.28 nm) were optimized.
Some past researches support the increase in the encapsulation
efﬁciency with increase in the polymer, which was true to some
extent in case of chitosan nanoparticles bearing 5-FU as
entrapment efﬁciency increased up to 69.18% till 1:3 ratio of
drug: polymer. The increase in the entrapment efﬁciency can
be attributed to the hydrophilicity of the chitosan polymer.
Also the use of chitosan correlates with the fact that it has very
promising tumor inhibition rates (Zhang et al., 2008a).
But contrary to that chitosan polymeric nanoparticles had
shown decrease in the entrapment efﬁciency (32.18 ± 0.47%)
with increase in the polymer ratio after 1:3, which can be
attributed to the more compact polymer coat, which limits
its entrapment. GL-EU nanoparticles have shown an entrap-
ment efﬁciency of 69.18 ± 1.89% and that decreased to
32.18 ± 0.47% for the drug: polymer ratio of 1:4. The opti-
mized ratio of 1:2 and 1:3 ratio of 5-FU were given primary
importance for further studies. Also the particle size of the
optimized ratios was found satisfactory which enables us to
select the both ratios for in vitro release studies.
3.5. Scanning electron microscopy
Scanning electron microscopy was performed for polymeric
nanoparticles with drug: polymer ratio of 1:3 to obtain more
information on the particle size and morphology. The photosof polymeric nanoparticles had shown that the formulated 5-
FU chitosan nanoparticles of different polymers were of sphe-
rical shape with size range from 102 to 139 nm, which were
shown in Fig. 4. Moreover the nanoparticles were observed
with smooth surface, which may contribute to its release of
the drug in a sustained manner when compared to the
nanoparticles having rough surface. This property was
evaluated thoroughly in the upcoming in vitro drug release
studies.
3.6. Enteric coated of optimized batches
Chitosan 5-FU nanoparticles with optimized drug: polymer
ratios of 1:3 (5-FU E1) and 1:2 (5-FU E2) were subjected to
enteric coating in order to protect the drug from getting
released at gastric pH and thereby allowing the coat to get dis-
solved at basic pH which allows the major amount to get
released at colon area.
3.7. In vitro drug release studies
The percentage drug release from 5-FU enteric coated
nanoparticles with drug: polymer ratio of 1:3 (5-FU E1) and
1:2 (5-FU E2) was observed by using dialysis bag technique
in various simulated ﬂuids. These were compared with the
plain chitosan nanoparticles, which were non-enteric coated
(5-FU NE). This was shown in Fig. 5. Both the ratios did
not release the drug till it reaches basic pH albeit minor amount
of 5% which may be attributed to the slight improper coating.
Drug started releasing only after 4 h once it enters simulat-
ed intestinal ﬂuid with pH 7.4. At 2 and 3 h time interval, drug
Figure 5 In vitro drug release proﬁle of nanoparticulate pellets in
various simulated ﬂuids. Results were presented as mean ± SD,
n= 3.
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not enteric coated that can be attributed to the fact that chi-
tosan polymer got degraded at gastric pH which is acidic and
started releasing the drug prior to colonic ﬂuid. 5-FU NE
nanoparticles released the drug up to 70% before reaching
the colonic ﬂuid which decreases the drug intended to lower
therapeutic effect.
The 5-FU E1 and 5-FU E2 nanoparticles showed consider-
able stability till it reaches basic pH and started releasing the
drug once they reach basic pH which may be attributed to
the carboxyl groups of Eudragit that ionize from neutral to
alkaline media. Once the Eudragit nanoparticles enter the neu-
tral and alkaline media, their integrity got disturbed due to the
ionization leading to the release of the nanoparticles. As a
result 5-FU E1 nanoparticles has shown enhanced drug release
82 ± 0.05% and 71 ± 1.02% at 24 h and 8 h respectively. The
5-FU E2 nanoparticles have shown a slight decrease in the
drug release (73 ± 0.89% at 24 h and 68 ± 0.25% at 8 h),
which may be attributed to the slightly improper drug entrap-
ment and also improper coating with chitosan.
5-FU E1 nanoparticles have shown enhanced drug release
when compared to the 5-FU E2 and 5-FU NE statistically
by paired t-test to determine whether two sets of data were sig-
niﬁcantly different from each other. The statistical analysis
using Minitab 17 and Minitab express has shown signiﬁcant
difference for 5-FU E1 nanoparticles. So these 5-FU E1
nanoparticles can be considered as a potential carrier, which
can release and localize the drug at colonic pH. Also the use
of chitosan leads to the sustained release and also beneﬁtted
by its tumor inhibiting property. The rationale of using enteric
coating with Eudragit-S100 was supported by preventing drug
degradation at gastric pH and allowing it to release once it
enters the neutral and alkaline medium.
4. Conclusion
It can be evident from the study that 5-FU was successfully
encapsulated in chitosan polymer by solvent evaporation
emulsiﬁcation method. 5-FU chitosan nanoparticles (drug:
polymer ratio of 1:3) yielded more entrapment efﬁciency, drug
content and cumulative drug release when compared to the
other polymeric nanoparticles with different polymer ratios.In vitro release concluded that 5-FU E1 nanoparticles released
drug after 4 h once it enters intestinal ﬂuid therefore protecting
the drug release in the gastric environment and enhancing its
drug release at colonic region that fulﬁlled our objective. We
can conclude that the formulated nanoparticles improved
localization of the drug at the colon area and also achieved
sustained release over a prolonged period of 24 h. This can
leads to the decreased toxicity to healthy cells as more amount
of drug is localized in the colon area. These changes beneﬁt the
patient in decreasing the dosing frequency and dose that can be
administered. So we can conclude that nanoparticles prepared
by this method using the same polymer with the optimized
ratio can represent as potential drug delivery approach for
effective delivery of the active pharmaceutical ingredient to
the colorectal tumors.
Recommended future research
Further in vivo studies can be carried to estimate the pharma-
cokinetic parameters and the sustained release property of the
5-FU E1 nanoparticles.
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